Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S003 - Best Evidence Based Opportunities for Cost-Effective Skin Care

Friday, February 16; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • To identify the evidenced best skin care
  • To assess cost effective care in light of best evidence available

Description

To optimize patient care, consideration of best evidence in context with cost effective care is critical. This session will highlight several skin diseases and clinical care scenarios to help practitioner develop paradigms of care. Disease discussed will include acne, connective tissue disease, onychomycosis, leg ulcers and skin cancer surgery. This session will also help practitioners better understand best use of topical steroids, lavatory evaluation of selected patients such as those taking isotretinion, and to understand benefits and challenges with rebate programs.

Disclosures

  • Adamson, Adewole Shomari, MD, MPP: no financial relationships exist with commercial interests.
  • Kia, Kevin, MD: Castle Biosciences, Inc – C(H);
  • Kirby, Joslyn S., MD: AbbVie – SP(H); Incyte Corporation – C(H);
  • Kirsner, Robert S., MD, PhD: AbbVie – C(Grants/Research Funding); Acelity – C(H); Cardinal Health – A(H); Harbor MedTech, Inc. – C(H); Keraderm – C(H); Kerecis Limited – A(H); Molynecke – A(H); National Healing Corp – A(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Maderal, Andrea, MD: no financial relationships exist with commercial interests.
  • Mostaghimi, Arash, MD, MPH: no financial relationships exist with commercial interests.
Schedule
Friday, February 16
9:00 AM
Dr. Kirsner / Welcome and Introduction
9:05 AM
Dr. Kia / Old vs. New Topical Care for Acne
9:25 AM
Dr. Adamson / Surgical Management of Skin Cancer
9:45 AM
Dr. Mostaghimi / Best Cost Effective Use of Topical Steroids
10:05 AM
Dr. Kirby / Cost Effective Laboratory work ups
10:25 AM
Dr. Kirsner / Cost Effective Care of Leg Ulcers
10:45 AM
Dr. Lebwohl / Rebate Care Programs: Are they Cost Effective Care?
11:05 AM
Dr. Maderal / Best Cost Effective Care of Lupus (and other connective tissue diseases)
11:25 AM
Dr. Kia / Oral vs. New Topical Care for Onychomycosis
11:45 AM
Dr. Kia / Summary and Conclusion
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 25B
  • CME Credits
    3.00
  • Type
    New
Directors/Co-Directors
  • Robert S. Kirsner, MD, PhD, FAAD
  • Kevin Kia, MD, FAAD
Speakers
  • Adewole Shomari Adamson, MD, MPP, FAAD
  • Andrea Maderal, MD, FAAD
  • Arash Mostaghimi, MD, MPH, FAAD
  • Joslyn S. Kirby, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout